Tislelizumab (BGB‐A317), an anti‐PD‐1 antibody, has been approved recently as a treatment for patients with classical Hodgkin's lymphoma who have failed at least one prior therapy or patients with locally advanced or metastatic urothelial carcinoma. This evidence concerns the gene PDCD1 and Hodgkins lymphoma.